Etoricoxib Versus Diclofenac Sodium Intramuscular Injections in Acute Orthopaedic Pain Management: A Randomized, Open-Label Pilot Trial
This randomized, open-label pilot trial comparing intramuscular etoricoxib and diclofenac sodium for acute orthopaedic pain found that while both drugs significantly reduced pain with no systemic adverse effects, etoricoxib demonstrated superior efficacy at the 12-hour mark but was associated with a higher incidence of injection-site discomfort.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Pain is a universal language, but the tools we use to silence it are often a matter of debate. In the world of broken bones, torn ligaments, and sudden joint inflammation, doctors rely heavily on a class of medicines called non-steroidal anti-inflammatory drugs. These work by blocking specific enzymes in the body that act like switches for inflammation and pain signals. For decades, a standard injection of diclofenac sodium has been the go-to solution in emergency rooms and clinics because it works quickly and is widely available. However, this older drug blocks both the pain switches and the protective switches that guard the stomach and heart, leading to concerns about long-term safety. Recently, a newer drug called etoricoxib has become available in an injectable form. It is designed to block only the pain switches, theoretically offering relief without the same risks. The question facing clinicians is whether this newer, more selective option works as well as the trusted veteran when given as a single shot for acute injury.
To answer this, a team of researchers at SRM Medical College Hospital in India set out to compare the two directly. They recruited 70 adults who had arrived with fresh, moderate-to-severe orthopedic pain, such as a fracture or a severe muscle strain. The patients were divided into two groups. One group received a single deep injection of 90 milligrams of etoricoxib, while the other received 75 milligrams of diclofenac sodium. The study was designed to be open, meaning both the doctors and the patients knew which drug they were getting, but the people measuring the pain and analyzing the data did not. The researchers tracked how much pain the patients felt at specific intervals: 30 minutes, 60 minutes, 12 hours, and 24 hours after the injection. They also kept a close watch for any side effects, from stomach upset to changes in kidney function, and asked patients to report any discomfort at the injection site itself.
The results showed that both drugs were highly effective at calming the storm of acute pain. Within an hour of the injection, patients in both groups reported a dramatic drop in their pain levels, and by the end of the first day, the average pain scores for the two groups were nearly identical. In terms of the overall ability to reduce pain over a full day, the two treatments performed equally well. This suggests that for a single dose, the newer drug is just as capable of providing relief as the long-standing standard. However, the story of how that relief unfolded over time told a different tale. While the average numbers looked the same, the pattern of pain relief was not. The researchers found that the two drugs followed different paths. Specifically, at the 12-hour mark, patients who received etoricoxib reported feeling significantly less pain than those who received diclofenac. This difference was not seen at the one-hour mark or at the 24-hour mark, but it appeared clearly in the middle of the day.
This mid-day advantage aligns with what is known about how the body processes these medicines. Diclofenac leaves the system relatively quickly, often dropping below effective levels within a few hours, which can lead to a return of pain before the next dose is due. Etoricoxib, by contrast, stays in the bloodstream much longer, maintaining its effect through the intermediate hours. The study suggests that while both drugs are excellent for immediate crisis management, etoricoxib may offer a smoother, more sustained experience for patients who need to wait longer before they can take another dose or see a doctor again.
Safety was another major focus of the investigation. The researchers were careful to check blood work for signs of kidney stress or other internal issues, and they found no significant differences between the two groups. Neither drug caused serious harm to the kidneys or blood cells in this single-dose setting. The only notable difference in safety was local. Patients receiving the etoricoxib injection were more likely to feel pain or discomfort right where the needle went in, with about 69 percent reporting some soreness compared to 43 percent in the diclofenac group. This discomfort was temporary and resolved on its own, but it is a factor doctors must weigh when choosing a treatment.
Ultimately, the study concludes that both injections are safe and effective tools for managing sudden, severe orthopedic pain. They are not rivals where one completely defeats the other; rather, they offer different profiles of relief. The newer drug provides a similar level of overall pain control but appears to hold its ground better in the hours between the initial shot and the next day. For patients with injuries that require sustained comfort without immediate follow-up care, this extended duration could be a meaningful benefit, provided they can tolerate a slightly higher chance of a sore spot where the injection was given. The findings do not declare one drug superior in every situation, but they do highlight that the choice between them can be tailored to the specific needs of the patient and the timeline of their recovery.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.